Illumina Raises Full-Year Guidance After Higher 2Q Profit, Revenue

Dow Jones
08/01

Illumina raised its full-year 2025 adjusted per-share guidance after reporting a higher profit and revenue in the second quarter.

The maker of gene-sequencing equipment and services said Thursday it now anticipates 2025 adjusted per-share earnings between $4.45 and $4.55, an increase from the company's previously-issued guidance of between $4.20 and $4.30.

Chief Executive Jacob Thaysen said the company is helping customers navigate a constrained research funding environment.

"Even in these challenging conditions, the team's focus on operational excellence helped drive margin expansion, enabling us to increase our expectations for the year," Thaysen said.

The San Diego, Calif.-based company swung to a second-quarter profit of $235 million, or $1.49 a share, compared with a loss of $1.99 billion, or $12.48 a share, a year earlier.

Excluding one-time items, per-share earnings were $1.19, above the $1.01 per share that analysts forecast, according to FactSet.

Revenue rose to $1.06 billion from $1.11 billion a year earlier. Analysts surveyed by FactSet had expected sales of $1.01 billion.

Illumina on Thursday said it now expects total company constant currency revenue to decline between 2.5% to 0.5%, up from its previously issued guidance of 3% to 1%.

Shares of Illumina have fallen 23% this year to date. Shares were up 4% at $107 in after-hours trading on Thursday.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10